Revolutionary Topical Treatment for Corneal Scarring
Losartan Ophthalmic Solution 0.08% for Fibrosis Prevention and Treatment
By: Dr. Ibrahim, Compounding Pharmacist
The Clinical Challenge: Corneal Scarring Fibrosis
Corneal scarring from trauma, infections, chemical burns, and surgical complications causes significant vision loss and has historically lacked effective pharmacologic treatment. While oral losartan treats hypertension systemically, it does not penetrate corneal tissue. This topical ophthalmic formulation delivers therapeutic concentrations directly to the cornea, targeting the TGF-beta signaling pathways that drive myofibroblast development and scarring.
Full-Thickness
100%
corneal penetration
Mechanism of Action: Multi-Pathway Anti-Fibrotic Targeting
1. Corneal Injury
Trauma, burns, infections trigger TGF-beta release
2. Topical Application
Six times daily dosing with 0.08% solution
TGF-Beta Blockade
Inhibits ERK signaling and myofibroblast formation
Transparency Restored
Myofibroblast apoptosis and scar resolution
TGF-Beta Signaling Inhibition
Blocks extracellular signal-regulated kinase (ERK) activation in noncanonical TGF-beta pathway, preventing fibroblast transformation into scar-forming myofibroblasts.
Myofibroblast Apoptosis
Induces programmed cell death of existing myofibroblasts by blocking their TGF-beta-dependent survival signaling, treating established scars.
Basement Membrane Surrogate
Functions as substitute for damaged epithelial basement membrane, regulating TGF-beta entry until natural membrane regeneration occurs.
Clinical Efficacy: Published Evidence
Multiple studies demonstrate significant corneal opacity reduction and visual acuity improvement across diverse pathologies.
Data from preclinical models and human case reports (2022-2025)
Key Clinical Advantages
Treats Established Scars
Unlike preventive treatments, losartan resolves existing corneal fibrosis, even scars present for years, through myofibroblast apoptosis induction.
Full-Thickness Penetration
Penetrates intact epithelium and entire stromal thickness to reach posterior cornea, treating both anterior and posterior fibrosis from single topical application.
Broad Clinical Applications
Effective across multiple etiologies: refractive surgery complications, viral keratitis, chemical burns, trauma, and persistent epithelial defects.
Published Clinical Evidence
Descemetorhexis Model (Exp Eye Res 2022)
Topical losartan 0.4 mg/mL six times daily produced markedly clearer peripheral corneas with significant reduction in central stromal opacity and decreased neovascularization after one month. Oral losartan showed no corneal effect.
Alkali Burn Study (Transl Vis Sci Tech 2022)
Losartan combined with prednisolone acetate additively decreased myofibroblast-associated fibrosis. Losartan alone was nearly as effective as the combination, demonstrating robust anti-fibrotic activity.
PRK Late Haze Prevention (J Refract Surg 2022)
Topical losartan significantly decreased corneal opacity (P = 0.04) and anterior stromal myofibroblast generation (P = 0.01) one month after high-correction PRK, with reduced collagen type IV deposition (P = 0.004).
First Human Case (J Refract Surg 2022)
Patient with severe LASIK haze treated with 0.8 mg/mL six times daily for 4.5 months achieved 20/30 uncorrected and 20/25 corrected visual acuity with significant haze reduction confirmed by multiple imaging modalities.
Herpes Keratitis Series (Case Rep Ophthalmol 2025)
Three patients with HSV or VZV corneal scarring who failed corticosteroid management showed improved visual acuity and reduced opacity after 4 to 9 months of treatment. One case involved 20-year-old scarring.
Long-Term Scar Resolution
Patient with three-year-old herpes zoster scar achieved 20/30 visual acuity within four months. Animal studies confirm efficacy when initiated one month after injury, demonstrating treatment of established fibrosis.
Clinical Applications and Dosing Protocol
Current Off-Label Uses
- • Refractive surgery complications (PRK late haze, LASIK scarring, SMILE complications)
- • Corneal lacerations and trauma
- • Viral keratitis scarring (HSV, VZV)
- • Bacterial, fungal, or Acanthamoeba keratitis scarring
- • Chemical and alkali burns
- • Persistent epithelial defects
Areas Under Investigation
- • TGF-beta-induced corneal dystrophies (Reis-Bucklers, lattice, granular)
- • Conjunctival fibrotic diseases (Stevens-Johnson, pemphigoid, trachoma)
- • Glaucoma surgery complications (bleb scarring, tube encapsulation)
- • Epidemic keratoconjunctivitis scars
- • Intraocular pressure reduction
Intact Epithelium Protocol
Standard dose: 0.8 mg/mL (0.08%) six times daily
Continue until clinical resolution of scarring
Treatment duration typically 4 to 6 months for significant scarring
Epithelial Defect Protocol
Reduced dose: 0.2 mg/mL six times daily until epithelial closure
Increase to 0.8 mg/mL after epithelium heals
Lower concentration prevents concentration-dependent epithelial toxicity
Critical Treatment Guidelines
⏱️ Treatment Duration Expectations
Do not discontinue after one month and assume treatment failure. Clinical response typically begins at 2 to 3 months. Severe scarring often requires 4 to 6 months before visible improvement. Patients may notice vision improvement before slit-lamp changes are apparent.
⚠️ Concentration Limits
Concentrations above 0.8 mg/mL should be avoided due to epithelial toxicity risk. Higher concentrations (8 mg/mL and above) caused persistent epithelial defects and severe discomfort in animal studies.
❄️ Storage Requirements
Store refrigerated at 2-8°C (36-46°F). Protect from light. Continue refrigerated storage between uses. Use aseptic technique for each application. Follow pharmacy-specific beyond-use dating guidelines.
Professional Compounding Excellence: MedTailor Standards
MedTailor delivers precision-compounded losartan ophthalmic solution for corneal scarring treatment, ensuring optimal concentration, sterility, and patient outcomes through pharmaceutical-grade compounding practices compliant with USP chapters 795 and 797.
Sterile Formulation
Compounded in ISO-certified cleanroom facilities with rigorous sterility testing for ophthalmic safety standards.
Precise Concentration
Exact 0.08% formulation based on published clinical protocols, with potency verification and stability testing.
Clinical Support
Comprehensive dosing guidance, administration training, and direct pharmacist consultation for optimal outcomes.
